期刊文献+

黑素瘤生物治疗的研究进展 被引量:3

The Research Progress of Biotherapy for Melanoma
下载PDF
导出
摘要 黑素瘤是皮肤侵袭性肿瘤,对放疗和化疗均不敏感。目前用于黑素瘤的生物治疗方法包括基因治疗、免疫治疗、针对肿瘤血供的治疗等,发挥在基因水平上调控黑素瘤的演进、增强肿瘤微环境对黑素瘤的免疫力以及抑制黑素瘤的血液供应的抗瘤作用。生物治疗以其比传统治疗有更好的靶向性与特异性的特点,成为黑素瘤传统治疗方法的有益补充。 Melanoma which is resistant to chemotherapies and radiotherapy is an invasive tumor of the skin.Biotherapies such as gene therapy,immunotherapy and therapy targeting at tumor′s blood-supply have shown potential effects on the therapy for melanoma——regulating the evolution of melanoma at gene level,enhancing the immunity of microenvironment against tumor,and obstructing the blood supply of melanoma.Due to superiority of specificity and targeting effects compared with traditional therapy,biotherapy has become a beneficial supplement to the traditional treatments.
出处 《医学综述》 2011年第12期1794-1797,共4页 Medical Recapitulate
基金 徐州市科技基金(XM08C060)
关键词 黑素瘤 基因治疗 免疫治疗 血管生成拟态 血管内皮生长因子 Melanoma Gene therapy Immunotherapy Vaseulogenic mimicry Vascular endothelial growth factor
  • 相关文献

参考文献30

  • 1Hocker TL,Singh MK,Tsao H.Melanoma genetics and therapeutic approaches in the 21st century:moving from the benchside to the bedside[J].J Invest Dermatol,2008,128(11):2575-2595.
  • 2白爱民,贾艳敏,张晓菁.siRNA为基础的RNAi在肿瘤基因治疗中的应用进展[J].中华肿瘤防治杂志,2007,14(12):953-955. 被引量:16
  • 3O′Connell MP,Fiori JL,Xu M,et al.The orphan tyrosine kinase receptor,ROR2,mediates Wnt5A signaling in metastatic melanoma[J].Oncogene,2010,29(1):34-44.
  • 4Singh S,Sadanandam A,Varney ML,et al.Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion[J].Int J Cancer,2010,126(2):328-336.
  • 5Filipowicz W,Bhattacharyya SN,Sonenberg N,et al.Mechanisms of post-transcriptional regulation by microRNAs:are the answers in sight?[J].Nat Rev Genet,2008,9(2):102-114.
  • 6Mueller DW,Bosserhoff AK.Role of miRNAs in the progression of malignant melanoma[J].Br J Cancer,2009,101(4):551-556.
  • 7Zheng JN,Pei DS,Mao LJ,et al.Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis[J].Cancer Gene Ther,2010,17(1):28-36.
  • 8Jiang G,Liu YQ,Wei ZP,et al.Enhanced anti-tumor activity by the combination of a conditionally replicating adenovirus mediated interleukin-24 and dacarbazin e against melanoma cells via induction of apoptosis[J].Cancer Lett,2010,294(2):220-228.
  • 9Zheng JN,Pei DS,Sun FH,et al.Inhibition of renal cancer cell growth by oncolytic adenovirus armed short hairpin RNA targeting hTERT gene[J].Cancer Biol Ther,2009,8(1):84-91.
  • 10Singh R,Paterson Y.Immunoediting sculpts tumor epitopes during immunotherapy[J].Cancer Res,2007,67(5):1887-1892.

二级参考文献63

  • 1赵秀兰,杜静,张诗武,刘易欣,王欣,孙保存.肝细胞肝癌中血管生成拟态的研究[J].中华肝脏病杂志,2006,14(1):41-44. 被引量:42
  • 2Verma S, Quirt I, McCready D, et al. Systematic review of systemie adjuvant therapy for patients at high risk for recurrent melanoma[J]. Cancer, 2006, 106(7):1431-1442.
  • 3Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change [J]. Cancer, 2007, 109(3): 455- 464.
  • 4Ives NJ, Stowe RL, Lorigan P, et al. Hemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2 621 patients [ J ]. J Clin Oncol, 2007, 25 (34) : 5426-5434.
  • 5Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer[J]. J Natl Cancer Inst, 1993, 85(8): 622- 632.
  • 6Khammari A, Nguyen JM, Pandolfino MC, et al. Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage Ⅲ melanoma[ J ]. Cancer Immunol Immunother, 2007, 56 ( 11 ) : 1853-1860.
  • 7Benlalam H, Vignard V, Khammari A, et al. Infusion of Melan- A/Mart-1 specific tumor-infiltrating lymphoeytes enhanced relapse- free survival of melanoma patients [ J ]. Cancer Immunol Immunother, 2007, 56(4) : 515-526.
  • 8Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes[ J]. Science, 2006, 314(5796) : 126-129.
  • 9Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologoaa CD4+ T cells against NY-ESO-1 [J]. N Engl J Med, 2008, 358 (25) : 2698-2703.
  • 10Dudley ME, Yang JC, Sherry, R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloa-blative chemoradiation preparative regimens [ J ]. J Clin Oncol, 2008, 26(32): 5233-5239.

共引文献17

同被引文献56

  • 1黄克伟,何侠.四肢恶性黑色素瘤转移规律的探讨[J].齐齐哈尔医学院学报,2004,25(11):1222-1223. 被引量:7
  • 2刘全忠,齐蔓莉,高硕,陈秋松.广泛转移恶性黑素瘤一例[J].中华皮肤科杂志,2004,37(12):741-741. 被引量:1
  • 3陈晓锋,顾振纶,杨海华,梁中琴.金荞麦Fr4对小鼠lewis肺癌细胞MMP-9、TIMP-1蛋白表达的影响[J].苏州大学学报(医学版),2005,25(3):383-386. 被引量:31
  • 4任萱,孙启明,林莉萍,丁健.肿瘤血管靶向药物的研究进展[J].生命科学,2007,19(4):427-432. 被引量:9
  • 5Donald D,Barry P, Cutaneous malignant melanoma:pathology and man- agement [ J ]. Surgery,2002,20 (6) : 145.
  • 6Roger M, Marie S, Judith M, et al. Treatment for metastatic malignant melanoma:Old drugs and new strategies[ J ]. Critical Reviews in Oncol- ogy/Hematology ,2010,74 ( 1 ) :28 - 29.
  • 7Queirolo P,Acquati M. Targeted therapies in melanoma [J]. Cancer Treat Rev, 2006,32(7) : 524-531.
  • 8Johansson M, Persson JL. Cancer therapy : targeting cell cycle regulators [J]. Anticancer Agents Med Chem, 2008,8(7) :723-731.
  • 9Murray AW, Marks D. Can sequencing shed light on cell cycling Nature [J]. 2001,409 (6822) : 844-846.
  • 10Caldon CE, Daly RJ,Sutherland RL, et al. Cell cycle con- trol in breast cancer ceils [J]. J Cell Biochem,2006,97(2) : 261-274.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部